IBDEI21H ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,35631,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,35631,1,3,0)
 ;;=3^Acute myeloblastic leukemia, in relapse
 ;;^UTILITY(U,$J,358.3,35631,1,4,0)
 ;;=4^C92.02
 ;;^UTILITY(U,$J,358.3,35631,2)
 ;;=^5001791
 ;;^UTILITY(U,$J,358.3,35632,0)
 ;;=C92.42^^189^2057^9
 ;;^UTILITY(U,$J,358.3,35632,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,35632,1,3,0)
 ;;=3^Acute promyelocytic leukemia, in relapse
 ;;^UTILITY(U,$J,358.3,35632,1,4,0)
 ;;=4^C92.42
 ;;^UTILITY(U,$J,358.3,35632,2)
 ;;=^5001803
 ;;^UTILITY(U,$J,358.3,35633,0)
 ;;=C92.52^^189^2057^7
 ;;^UTILITY(U,$J,358.3,35633,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,35633,1,3,0)
 ;;=3^Acute myelomonocytic leukemia, in relapse
 ;;^UTILITY(U,$J,358.3,35633,1,4,0)
 ;;=4^C92.52
 ;;^UTILITY(U,$J,358.3,35633,2)
 ;;=^5001806
 ;;^UTILITY(U,$J,358.3,35634,0)
 ;;=C92.11^^189^2057^18
 ;;^UTILITY(U,$J,358.3,35634,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,35634,1,3,0)
 ;;=3^Chronic myeloid leukemia, BCR/ABL-positive, in remission
 ;;^UTILITY(U,$J,358.3,35634,1,4,0)
 ;;=4^C92.11
 ;;^UTILITY(U,$J,358.3,35634,2)
 ;;=^5001793
 ;;^UTILITY(U,$J,358.3,35635,0)
 ;;=C92.12^^189^2057^19
 ;;^UTILITY(U,$J,358.3,35635,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,35635,1,3,0)
 ;;=3^Chronic myeloid leukemia, BCR/ABL-positive, in relapse
 ;;^UTILITY(U,$J,358.3,35635,1,4,0)
 ;;=4^C92.12
 ;;^UTILITY(U,$J,358.3,35635,2)
 ;;=^5001794
 ;;^UTILITY(U,$J,358.3,35636,0)
 ;;=C92.21^^189^2057^13
 ;;^UTILITY(U,$J,358.3,35636,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,35636,1,3,0)
 ;;=3^Atypical chronic myeloid leukemia, BCR/ABL-neg, in remission
 ;;^UTILITY(U,$J,358.3,35636,1,4,0)
 ;;=4^C92.21
 ;;^UTILITY(U,$J,358.3,35636,2)
 ;;=^5001796
 ;;^UTILITY(U,$J,358.3,35637,0)
 ;;=C92.22^^189^2057^14
 ;;^UTILITY(U,$J,358.3,35637,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,35637,1,3,0)
 ;;=3^Atypical chronic myeloid leukemia, BCR/ABL-neg, in relapse
 ;;^UTILITY(U,$J,358.3,35637,1,4,0)
 ;;=4^C92.22
 ;;^UTILITY(U,$J,358.3,35637,2)
 ;;=^5001797
 ;;^UTILITY(U,$J,358.3,35638,0)
 ;;=C93.01^^189^2057^3
 ;;^UTILITY(U,$J,358.3,35638,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,35638,1,3,0)
 ;;=3^Acute monoblastic/monocytic leukemia, in remission
 ;;^UTILITY(U,$J,358.3,35638,1,4,0)
 ;;=4^C93.01
 ;;^UTILITY(U,$J,358.3,35638,2)
 ;;=^5001820
 ;;^UTILITY(U,$J,358.3,35639,0)
 ;;=C93.02^^189^2057^4
 ;;^UTILITY(U,$J,358.3,35639,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,35639,1,3,0)
 ;;=3^Acute monoblastic/monocytic leukemia, in relapse
 ;;^UTILITY(U,$J,358.3,35639,1,4,0)
 ;;=4^C93.02
 ;;^UTILITY(U,$J,358.3,35639,2)
 ;;=^5001821
 ;;^UTILITY(U,$J,358.3,35640,0)
 ;;=C93.11^^189^2057^21
 ;;^UTILITY(U,$J,358.3,35640,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,35640,1,3,0)
 ;;=3^Chronic myelomonocytic leukemia, in remission
 ;;^UTILITY(U,$J,358.3,35640,1,4,0)
 ;;=4^C93.11
 ;;^UTILITY(U,$J,358.3,35640,2)
 ;;=^5001823
 ;;^UTILITY(U,$J,358.3,35641,0)
 ;;=C93.12^^189^2057^20
 ;;^UTILITY(U,$J,358.3,35641,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,35641,1,3,0)
 ;;=3^Chronic myelomonocytic leukemia, in relapse
 ;;^UTILITY(U,$J,358.3,35641,1,4,0)
 ;;=4^C93.12
 ;;^UTILITY(U,$J,358.3,35641,2)
 ;;=^5001824
 ;;^UTILITY(U,$J,358.3,35642,0)
 ;;=C93.91^^189^2057^38
 ;;^UTILITY(U,$J,358.3,35642,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,35642,1,3,0)
 ;;=3^Monocytic leukemia, unspecified in remission
 ;;^UTILITY(U,$J,358.3,35642,1,4,0)
 ;;=4^C93.91
 ;;^UTILITY(U,$J,358.3,35642,2)
 ;;=^5001829
 ;;^UTILITY(U,$J,358.3,35643,0)
 ;;=C93.92^^189^2057^37
 ;;^UTILITY(U,$J,358.3,35643,1,0)
 ;;=^358.31IA^4^2
 ;;
 ;;$END ROU IBDEI21H
